Updated KEYNOTE-365 Cohort I Results: Pembrolizumab + Carboplatin/Etoposide vs Chemotherapy Alone for Neuroendocrine Prostate Cancer. Presented by Dr. Gunhild von Amsberg, #ESMO26

UroToday.com· @urotoday · X·2026-10-24 21:30· 1 day agoScore70

Body

Updated KEYNOTE-365 Cohort I Results: Pembrolizumab + Carboplatin/Etoposide vs Chemotherapy Alone for Neuroendocrine Prostate Cancer. Presented by Dr. Gunhild von Amsberg, #ESMO26 written coverage by @zklaassen_md > https://bit.ly/4ep7B7i #ProstateCancer #NEPC @myESMO

125 views · 0 likes · 0 reposts · 0 replies

Conference abstracts

2217RONCT04746300matched by Rapid oral: Genitourinary tumours, prostate, penile and testis

Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)

https://esmocongress.esmo.org

Source: UroToday.com · x.com